Apellis Pharmaceuticals, set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, is gaining attention as a global leader in complement science. The company has achieved significant milestones, including maintaining a 60% market share and reporting approximately $689 million in U.S. net product revenues, driven by its innovative therapies. Apellis continues to strategically position itself for future growth with regulatory plans for new product offerings and a focus on unmet medical needs.
“Apellis Pharmaceuticals, Inc. · will present at · the 44th Annual J.P. Morgan Healthcare Conference · January 12, 2026 at 11:15 a.m. PT”
“Apellis Pharmaceuticals, Inc. · is a · global biopharmaceutical company · leading the way in complement science to develop life-changing therapies”
“Apellis Pharmaceuticals, Inc. · has · two C3-targeting medicines · approved to treat four serious diseases”
“Apellis Pharmaceuticals, Inc. · ushered in · the first new class of complement medicine · in 15 years”
“Apellis Pharmaceuticals, Inc. · includes · the first-ever therapy for geographic atrophy · a leading cause of blindness”
“Apellis Pharmaceuticals, Inc. · includes · the first treatment for patients 12 and older with C3G or primary IC-MPGN · two severe, rare kidney diseases”
“Apellis Pharmaceuticals · reported · U.S. net product revenues · approximately $689 million”
“Apellis · maintained · market share · 60%”
“Apellis · planned · regulatory submission · for prefilled syringe for SYFOVRE in the first half of 2026”
“Apellis · expected to make · OCT-F available · for research use in the second half of 2026”
“Apellis · anticipates · topline data · from the Phase 2 study of SYFOVRE + APL-3007 in 2027”
“Apellis Pharmaceuticals Inc · is · a commercial-stage biopharmaceutical company”